E

Lining up multiple approaches in AML

Novel approaches in AML seek to overcome the challenges of the past and improve clinical outcomes.

January 23, 2020
E

Will 2020 be an inflection year for Kura Oncology?

Update on Kura Oncology's progress with tipifarnib and their emerging pipeline

January 16, 2020
E

Lining up new developments in the treatment of GVHD

Following the recent failure of Incyte's itacitinib in acute GVHD, we look at promising early developments following in their wake.

January 13, 2020
E

The Evolving Competitive Landscape for TIM-3

TIM-3 may have a role to play in myeloid hematologic malignancies such as AML and MDS. We explore the scientific rationale, competitive landscape, and initial clinical data.

January 8, 2020
E

Novel agents and targets – Part 1

Some novel targets, new agents and some twists in the tale to consider in hematologic malignancies

December 19, 2019
E

The dog that didn’t bark

A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead

December 17, 2019
E

In Plain Sight

A look at some of the highly ranked clinical data presented over the weekend in Orlando

December 9, 2019
E

Friday Scientific Workshops are the Perfect Warm-Up act to ASH19

Science Friday at ASH19 with a look at various lymphoma and myeloma developments

December 7, 2019
E

Update on the KRAS Runners and Riders

A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.

December 3, 2019
E

10 early phase ASH19 abstracts with a difference

A look at off Broadway abstracts on early new product development and scientific findings of interest

November 26, 2019
E

9 up and coming non-T cell based immunotherapy approaches

Non-T cell based immunotherapies that could be promising in hematologic malignancies

November 21, 2019
E

ASH19 10 innovative approaches in Hematologic Malignancies

Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19

November 19, 2019
E

New developments in targeting the B cell receptor pathway

It's time for an update on new participants to the runners and riders in CLL and NHL. Some interesting findings with BTK inhibitors to consider here!

November 7, 2019